PA-PPG
24.5.2022 14:33:14 CEST | Business Wire | Press release
PPG (NYSE:PPG) today announced that it has committed to setting near-term company-wide emission reductions in line with climate science through the Science Based Target initiative (SBTi), which is an organization that helps companies define their decarbonization strategy and reduce the impacts of climate change.
PPG has an existing goal to reduce GHG emissions intensity by 15% by 2025 from a 2017 baseline, achieving a 9.7% reduction in 2021. The company has long reported emissions intensity from its own operations (Scope 1 emissions) and purchased electricity, steam, heating and cooling (Scope 2 emissions) and plans to unveil its new 2030 goals over the coming months. Moving forward, PPG is prioritizing evaluating indirect emissions that are from sources outside of the organization that PPG does not own or control, including raw materials, use of sold products, and product end-of-life (Scope 3 emissions).
“In this critical moment for climate change, we are committed to further evaluating and reducing emissions throughout our value chain,” said Diane Kappas, PPG vice president, Global Sustainability. “We are working across our organization to define additional actions we can take to help prevent the earth from warming more than 1.5 degrees Celsius. Following our validation work with SBTi and an emissions analysis, we intend to announce new, aggressive 2030 goals that will define our decarbonization strategy to help protect the planet for current and future generations.”
PPG also released its 2021 Environmental, Social and Governance (ESG) Report, which details advancements in its sustainable innovations, board governance of ESG, efforts to reach its 2025 sustainability goals and further actions to support customers’ sustainability goals. The full report is available at sustainability.ppg.com .
“Sustainability is at the heart of our purpose to protect and beautify the world,” said Kappas. “Our employees’ hard work and dedication helped us meet and surpass several of our near-term 2025 goals, and we continue to look for additional ways to reduce our emissions and overall environmental impact. While we are proud of our achievements, we recognize that now is the time for further action. We look forward to unveiling science-based targets as we complete the validation process.”
The latest report highlights PPG’s environmental actions and innovations globally. Key highlights include:
- Introduced PPG ERGOLUXE™ powder coatings, which offer first-pass transfer efficiency rates of up to 85% and the ability to reuse overspray. PPG ErgoLuxe Eco contains up to 13% recycled polyethylene terephthalate (rPET). Since 2017, PPG has used more than 6 million pounds of rPET to manufacture its coatings.
- Launched COMEX® TOP paint by PPG, which contributes to the circular economy by incorporating recycled tires, saving more than 270,000 tires from landfills since the product was introduced in 2021. The product is intended for application on roofs and provides thermal insulation, resulting in emissions reduction through energy savings.
- Implemented the Zero Discharge Project at Architectural Coatings facilities in the U.S. and Canada, enabling PPG to recycle and reuse more than 1.7 million gallons of water in its manufacturing process over the past two years.
- Installed a combined heat and power (CHP) unit at the Caivano, Italy, facility, creating an efficiency improvement equating to an annual reduction of approximately 1,100 metric tons of carbon dioxide (CO2 ).
- Invested more than $8.7 million between 2015 and 2021 in PPG’s global COLORFUL COMMUNITIES® initiative.
In 2021, PPG reduced process waste, increased renewable energy use in its facilities and increased sales from sustainably advantaged products. Highlights include:
- 38% of sales from sustainably advantaged products against the goal of 40% by 2025;
- 24% of electricity usage from renewable energy sources against the goal of 25% by 2025;
- 40% of manufacturing and research and development facilities with zero process waste to landfill, above the goal of 35% by 2025; and
- 37% reduction in waste disposal intensity from the 2017 baseline, above the goal of 25% by 2025.
To create strong and equitable communities, PPG worked to engage employees and diversify its recruiting and talent pools. Efforts focused on diversity, equity and inclusion (DE&I) include:
-
Unveiled new DE&I commitments:
- Achieve 34% to 36% representation of non-frontline global female professionals by 2025. PPG achieved 30% as of December 31, 2021.
- Increase representation of Black, Latino and Asian employees by 45% to 55% across our non-frontline, U.S.-based employee population (using January 1, 2021, as our baseline). At the end of 2021, PPG increased non-frontline Black employees by 13%, Latino employees by 9% and Asian employees by 8%.
- Achieve total global employee resource network (ERN) and DE&I capability-building participation of 50% by 2025. As of the end of 2021, PPG achieved 33% of this goal.
- Published the first PPG DE&I Report .
- Grew eight global ERNs to include more than 7,000 employee members across more than 60 countries.
- Invested $7.4 million through 2021 to advance racial equity in the U.S. by funding educational pathways for Black communities and people of color.
PPG’s 2021 reporting disclosures align with the Global Reporting Initiative (GRI) Standards and the Sustainability Accounting Standards Board (SASB) chemical standard. The company also strengthened its reporting against the United Nations Sustainable Development Goals (UN SDGs) and reported qualitative climate-related risks according to the Task Force on Climate-Related Financial Disclosures (TCFD).
To learn more about ESG at PPG and explore the report, visit sustainability.ppg.com .
PPG: WE PROTECT AND BEAUTIFY THE WORLD™
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for nearly 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 75 countries and reported net sales of $16.8 billion in 2021. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com .
We protect and beautify the world and ErgoLuxe are trademarks and Colorful Communities and the PPG Logo are registered trademarks of PPG Industries Ohio, Inc.
Comex is a registered trademark of Consorcio Comex, S.A. de C.V.
CATEGORY Sustainability
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
